Clinical Trial Update: Pediatric Pharmacokinetics And Safety Study Of Moxidectin [Phase 2]

View source ↗

Summary

Pfizer's Phase 2 pediatric pharmacokinetics and safety study of moxidectin for onchocerciasis has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Onchocerciasis

Drugs mentioned

• Moxidectin (moxidectin)

Snippet

Sponsor: Pfizer | Conditions: Onchocerciasis | Phase 2 | Status: WITHDRAWN